Figure 3:

Effect of treatment on fall exacerbations rates within key sensitization subgroups based on results of recursive partitioning

Probability of a fall exacerbation by treatment group within key subgroups. Subgroups are based on level of aeroallergen sensitization, total IgE and total eosinophils count. The points are least squares estimates from the site adjusted logistic models. Odds ratio, confidence interval, and associated p-value comparing omalizumab vs. placebo are annotated. Subgroup p-value <0.10 indicates significantly differential effect between 1 to 3 and ≥ 4 aeroallergen sensitizations.